ArticleJournal of clinical medicine2023
Perimount MAGNA Ease vs. INSPIRIS Resilia Valve: A PS-Matched Analysis of the Hemodynamic Performances in Patients below 70 Years of Age.
Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Early and late clinical outcomes and cost-effectiveness of aortic valve replacement using the Inspiris Resilia bioprosthesis : A systematic review and meta-analysis.Journal of cardiothoracic surgery · 2025Pooled it
- Valve-Related Outcomes up to Six Years of a Next-Generation Bovine Pericardial Bioprosthesis Compared with Its Predecessor: A Propensity-Matched Analysis.Medical sciences (Basel, Switzerland) · 2026Article
- Real-world early- to midterm outcomes of aortic valve replacement using novel tissue technology bioprosthesis at a high-volume center.JTCVS open · 2026Article
- Clinical Outcomes of a New-Generation Surgical Aortic Bioprosthesis: A Noninferiority Study.JTCVS open · 2026Article
- Propensity-adjusted 8-year outcomes following bioprosthetic aortic valve replacement: The influence of novel anticalcification technology.JTCVS open · 2026Article
- Functional Performance of 2 Different Transcatheter Heart Valve Models as Valve-in-Valve Before and After Expansion of the Inspiris Resilia: An In Vitro Study.Interdisciplinary cardiovascular and thoracic surgery · 2026Article
- Exploratory Cost-Effectiveness of a Novel Bioprosthetic Valve for Surgical Aortic Valve Replacement in Spain.PharmacoEconomics - open · 2025Article
- Mid-Term Outcomes After Aortic Valve Replacement in Patients Under 70: A Comparative Study of INSPIRIS RESILIA Versus PERIMOUNT MAGNA EASE Bioprostheses.Interdisciplinary cardiovascular and thoracic surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundDuring the past decade, the Perimount Magna Ease (PME) bioprosthesis has been implanted worldwide for aortic valve replacement (AVR). Recently, the INSPIRIS Resilia (IR) valve has been introduced as the newest generation of pericardial bioprostheses. However, few data have been reported about patients ≤70 years, and no comparisons in terms of hemodynamic performance between these two bioprostheses have been ever reported.
methodsPatients aged <70 years undergoing AVR were considered for comparison between PME (
resultsA total of 122 pairs with similar baseline characteristics were obtained from the PS-matching. The two prostheses showed comparable hemodynamic performances at one year (Gmean: 11.3 ± 3.5 mmHg vs. 11.9 ± 5.4 mmHg;
conclusionsThis first PS-matched analysis demonstrated that the newly developed IR valve achieves the same safety and efficacy of the PME valve during mid-term follow-up in patients aged <70 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.